Glaukos Corporation filed an 8-K to disclose an investor presentation dated May 2026, highlighting its pipeline progress including FDA approval for iDose TR re-administration and Phase 3 data for iStent infinite.
Key takeaways
iDose TR became the first and only glaucoma procedural pharmaceutical FDA-approved for re-administration in January 2026.
New Phase 3 data analysis demonstrates iDose TR non-inferiority to topical timolol at 3 years.
iStent infinite completed enrollment in a mild-to-moderate glaucoma study for potential label expansion.
The company reported 30% topline growth for 2025 and a 10-year revenue CAGR of 20%.
Pipeline includes 13 disclosed programs and 12 currently commercialized products.